Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

• Status: Completed
• Trial end date: 2020-01-22
• Target enrollment: 0
• Participant gender: All

Summary

Preventing hypoxemia is one of the major goal of studies for bronchoscopic sedation. Dexmedetomidine is a sedative agents via α2 adrenergic agonist, with little respiratory suppression. In the preset study, we evaluate the safety and feasibility of the Dexmedetomidine in the specific bronchoscopic procedure, endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: Dexmedetomidine; Propofol

Criteria

Inclusion Criteria:

• Patients undergoing elective bronchoscopy and sedation

Exclusion Criteria:

• Age less than 20 years

• American Society of Anaesthesiologists (ASA) physical status classification IV or V

• Mallampati score of 4

• Severe sleep apnoea syndrome (apnoea-hypopnea index more than 40)

• Body mass index more than 42 in males or 35 in females

• Neurologic disorders or other conditions contributing to difficulty in assessing response

• Forced expiratory vital capacity (FVC) less than 15 ml/kg body weight, forced expiratory volume in one second (FEV1) less than 1000 ml, or FEV1/FVC less than 35%

• History of second or third degree atrioventricular block, heat rate less than 50 beat per minute or systolic blood pressure less than 90 mmHg

• Pregnancy

• Patients with a known history of allergy to the study drugs, or to eggs, soybeans or sulfite products